Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has started a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.
Subscribe to our email newsletter
The new development program will examine direct (intravesical) administration of LOR-2040 into the bladder as a treatment for superficial or non-invasive bladder cancer. Formal toxicology evaluation, which is currently in progress, will be used to determine the appropriate human dose and dose schedule for LOR-2040 with this route of administration.
Results of these studies will be used in support of an investigational new drug (IND) application for the use of LOR-2040 in the treatment of bladder cancer. Lorus intends to submit the IND during the third quarter of 2008, following successful completion of the toxicology program.
Aiping Young, president and CEO of Lorus, said: “I am pleased that we have initiated the studies that explore a novel way of administering LOR-2040 directly to bladder tumors and that we are on schedule to advance LOR-2040 in this indication.”